nach oben

Erschienen in:

01.02.2022 | Original Paper

The role of mineralocorticoids and glucocorticoids under the impact of 11β-hydroxysteroid dehydrogenase in human breast lesions

verfasst von: Mingzhen Cai, Keely McNamara, Yuto Yamazaki, Narumi Harada, Minoru Miyashita, Hiroshi Tada, Takanori Ishida, Hironobu Sasano

Erschienen in: Medical Molecular Morphology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

We attempted to explore the possible involvement of the in situ availability of mineralocorticoids and mineralocorticoid receptor (MR) in the pathogenesis of mammary ductal carcinoma. We also explored their individual profiles among different subtypes of invasive ductal carcinomas of no special type (IDC-NST) by evaluating the status of MR, Glucocorticoid receptor (GR), and 11β hydroxysteroid dehydrogenase (HSD) 1/2 at each stage of the putative cascade of the mammary ductal proliferative disorders. In this study, IDC-NST, ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH), and non-pathological breast tissues were all evaluated by immunohistochemistry. MR was significantly lower in ADH than in DCIS or IDC-NST. 11βHSD2 was significantly lower in ADH than normal breast tissue and 11βHSD1 was significantly higher in DCIS than normal, ADH, or IDC-NST. MR in progesterone receptor (PR)-positive IDC-NST cases tended to be associated with the Ki-67 labeling index. Results of the present study demonstrated that the status of MR and GR in conjunction with the 11βHSDs was correlated with the development of low-grade proliferative disorders in mammary glands. In addition, the potential crosstalk between MR and PR could also influence cell proliferation of breast carcinoma cells but further investigations are required for clarification.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMedCrossRef

WHO classification of tumours editorial board (2019) Breast tumours. WHO classification of tumours, 5th ed, vol 2. International Agency for Research on Cancer, Lyon

Bombonati A, Sgroi DC (2011) The molecular pathology of breast cancer progression. J Pathol 223:308–318CrossRef

Collins LC (2018) Precursor lesions of the low-grade breast neoplasia pathway. S Surg Pathol Clin 11:177–197CrossRef

Malhotra GK, Zhao X, Band H, Band V (2010) Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 10:955–960PubMedPubMedCentralCrossRef

Rakha EA (2012) The low nuclear grade breast neoplasia family. Diagn Histopathol 18:124–132CrossRef

Gordian-Arroyo AM, Zynger DL, Tozbikian GH (2019) Impact of the 2018 ASCO/CAP HER2 guideline focused update. Am J Clin Pathol 152:17–26PubMedCrossRef

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

10.

Sun Z, Prat A, Cheang MC, Gelber RD, Perou CM (2015) Chemotherapy benefit for ‘ER-positive’breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER. Ann Oncol 26:70–74PubMedPubMedCentralCrossRef

11.

Tang P, Tse GM (2016) Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med 140:806–814PubMedCrossRef

12.

Oftedal OT (2002) The mammary gland and its origin during synapsid evolution. J Mamm Gland Biol Neoplasia 7:225–252CrossRef

13.

Weng T, Wu P, Zhang W, Zheng Y, Li Q, Jin R, Chen H, You C, Guo S, Han C, Wang X (2020) Regeneration of skin appendages and nerves: current status and further challenges. J Transl Med 18:53PubMedPubMedCentralCrossRef

14.

Widelitz RB, Veltmaat JM, Mayer JA, Foley J, Chuong C-M (2007) Mammary glands and feathers: comparing two skin appendages which help define novel classes during vertebrate evolution. Semin Cell Dev Biol 18:255–266PubMedPubMedCentralCrossRef

15.

Ashby KL (2004) Mammary glands. Encyclopedia of women’s health. Springer, Boston, pp 748–750CrossRef

16.

Sasano H, Fukushima K, Sasaki I, Matsuno S, Nagura H, Krozowski ZS (1992) Immunolocalization of mineralocorticoid receptor in human kidney, pancreas, salivary, mammary and sweat glands: a light and electron microscopic immunohistochemical study. J Endocrinol 132(2):305–310PubMedCrossRef

17.

Niculet E, Bobeica C, Tatu AL (2020) Glucocorticoid-induced skin atrophy: the old and the new. Clin Cosmet Investig Dermatol 13:1041–1050PubMedPubMedCentralCrossRef

18.

Conzen SD (2008) Minireview: nuclear receptors and breast cancer. Mol Endocrinol 22:2215–2228PubMedPubMedCentralCrossRef

19.

Vaidya JS, Baldassarre G, Thorat MA, Massarut S (2010) Role of glucocorticoids in breast cancer. Curr Pharm Des 16:3593–3600PubMedCrossRef

20.

Kenouch S, Lombes M, Delahaye F, Eugene E, Bonvalet JP, Farman N (1994) Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 79:1334–1341PubMed

21.

Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS (1994) Cloning and tissue distribution of the human 1 lβ-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11–R17PubMedCrossRef

22.

Stewart PM, Krozowski ZS (1999) 11 beta-hydroxysteroid dehydrogenase. Vitam Horm 57:249–324PubMedCrossRef

23.

Heussner K, Ruebner M, Huebner H, Rascher W, Menendez-Castro C, Hartner A, Fahlbusch FB, Rauh M (2016) Species differences of 11beta-hydroxysteroid dehydrogenase type 2 function in human and rat term placenta determined via LC-MS/MS. Placenta 37:79–84PubMedCrossRef

24.

Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268–275PubMedCrossRef

25.

Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4:965–994PubMedPubMedCentralCrossRef

26.

Galigniana MD, Erlejman AG, Monte M, Gomez-Sanchez C, Piwien-Pilipuk G (2010) The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol Cell Biol 30:1285–1298PubMedCrossRef

27.

Nishi M, Ogawa H, Ito T, Matsuda K-I, Kawata M (2001) Dynamic changes in subcellular localization of mineralocorticoid receptor in living cells: in comparison with glucocorticoid receptor using dual-color labeling with green fluorescent protein spectral variants. Mol Endocrinol 15:1077–1092PubMedCrossRef

28.

JÄÄSkelÄInen A, Jukkola A, Haapasaari K-M, Auvinen P, Soini Y, Karihtala P, (2019) Cytoplasmic mineralocorticoid receptor expression predicts dismal local relapse-free survival in non-triple-negative breast cancer. Anticancer Res 39:5879–5890CrossRef

29.

Lother A (2020) Mineralocorticoid receptors. Circ Res 127:354–356PubMedCrossRef

30.

Petrillo MG, Jewell CM, Oakley RH, Cidlowski JA (2020) OR12-02 When the glucocorticoid receptor meets the mineralocorticoid receptor in the nucleus of human cells. J Endocr Soc 4(Suppl 1):OR12-02PubMedCentralCrossRef

31.

Kingsley-Kallesen M, Mukhopadhyay SS, Wyszomierski SL, Schanler S, Gn S, Rosen JM (2002) The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol Endocrinol 16:2008–2018PubMedCrossRef

32.

Sasano H, Frost AR, Saitoh R, Matsunaga G, Nagura H, Krozowski ZS, Silverberg SG (1997) Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Anticancer Res 17:2001–2007PubMed

33.

Sasaki Y, Miki Y, Hirakawa H, Onodera Y, Takagi K, Ji A, Honma S, Ishida T, Watanabe M, Sasano H (2010) Immunolocalization of estrogen-producing and metabolizing enzymes in benign breast disease: comparison with normal breast and breast carcinoma. Cancer Sci 101:2286–2292PubMedCrossRef

34.

Trabert B, Sherman ME, Kannan N, Stanczyk FZ (2020) Progesterone and breast cancer. Endocr Rev 41:320–344CrossRef

35.

Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292PubMedPubMedCentralCrossRef

36.

Sasano H, Miki Y, Nagasaki S, Suzuki T (2009) In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int 59:777–789PubMedCrossRef

37.

Kanai A, McNamara KM, Iwabuchi E, Miki Y, Onodera Y, Guestini F, Khalid F, Sagara Y, Ohi Y, Rai Y, Yamaguchi R, Tanaka M, Miyashita M, Ishida T, Sasano H (2020) Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling. Breast Cancer Res Treat 180:97–110PubMedCrossRef

38.

Saito R, Miki Y, Abe T, Miyauchi E, Abe J, Nanamiya R, Inoue C, Sato I, Sasano H (2020) 11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. Br J Cancer 123:61–71PubMedPubMedCentralCrossRef

39.

Ogias D, Rattes IC, Hosoya LYM, Zulian JG, Yan CYI, Gama P (2018) Neonatal- maternal separation primes zymogenic cells in the rat gastric mucosa through glucocorticoid receptor activity. Sci Rep 8:9823PubMedPubMedCentralCrossRef

40.

Klöppel G, La Rosa S (2018) Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 472:341–349PubMedCrossRef

41.

Reid MD, Bagci P, Ohike N, Saka B, Seven IE, Dursun N, Balci S, Gucer H, Jang K-T, Tajiri T (2015) Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol 28:686–694PubMedCrossRef

42.

Allred DC (2010) Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer. Mod Pathol 23:S52–S59PubMedCrossRef

43.

Cat AND, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F (2010) The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 24:2454–2463CrossRef

44.

Shi S-R, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741–748PubMedCrossRef

45.

Konosu-Fukaya S, Nakamura Y, Satoh F, Felizola SJA, Maekawa T, Ono Y, Morimoto R, Ise K, Takeda K-I, Katsu K, Fujishima F, Kasajima A, Watanabe M, Arai Y, Gomez-Sanchez EP, Gomez-Sanchez CE, Doi M, Okamura H, Sasano H (2015) 3β-Hydroxysteroid dehydrogenase isoforms in human aldosterone-producing adenoma. Mol Cell Endocrinol 408:205–212PubMedCrossRef

46.

Nie H, Li J, Yang XM, Cao QZ, Feng MX, Xue F, Wei L, Qin W, Gu J, Xia Q (2015) Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. Hepatology 62:1145–1159PubMedCrossRef

47.

Connell JM, Davies E (2005) The new biology of aldosterone. J Endocrinol 186:1–20PubMedCrossRef

48.

Queisser N, Schupp N, Schwarz E, Hartmann C, Mackenzie GG, Oteiza PI (2017) Aldosterone activates the oncogenic signals ERK1/2 and STAT3 via redox-regulated mechanisms. Mol Carcinog 56:1868–1883PubMedCrossRef

49.

Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, Avino S, De Marco P, Bussolati B, Maggiolini M, De Francesco EM (2016) GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. Oncotarget 7:94–111PubMedCrossRef

50.

Pippal JB, Cheung CMI, Yao Y-Z, Brennan FE, Fuller PJ (2011) Characterization of the zebrafish (Danio rerio) mineralocorticoid receptor. Mol Cell Endocrinol 332:58–66PubMedCrossRef

51.

Sturm A, Bury N, Dengreville L, Fagart J, Flouriot G, Rafestin-Oblin ME, Prunet P (2005) 11-deoxycorticosterone is a potent agonist of the rainbow trout (Oncorhynchus mykiss) mineralocorticoid receptor. Endocrinology 146:47–55PubMedCrossRef

52.

Sugimoto A, Oka K, Sato R, Adachi S, Baker ME, Katsu Y (2016) Corticosteroid and progesterone transactivation of mineralocorticoid receptors from Amur sturgeon and tropical gar. Biochem J 473:3655–3665PubMedCrossRef

53.

Katsu Y, Kohno S, Oka K, Lin X, Otake S, Pillai NE, Takagi W, Hyodo S, Venkatesh B, Baker ME (2019) Transcriptional activation of elephant shark mineralocorticoid receptor by corticosteroids, progesterone, and spironolactone. Sci Signal 12:eaar2668PubMedCrossRef

54.

Wambach G, Higgins JR (1978) Antimineralocorticoid action of progesterone in the rat: correlation of the effect on electrolyte excretion and interaction with renal mineralocorticoid receptors. Endocrinology 102:1686–1693PubMedCrossRef

55.

Landau RL, Lugibihl K (1958) Inhibition of the sodium-retaining influence of aldosterone by progesterone. J Clin Endocrinol Metab 18:1237–1245PubMedCrossRef

56.

Sharp GW, Komack CL, Leaf A (1966) Studies on the binding of aldosterone in the toad bladder. J Clin Invest 45:450–459PubMedPubMedCentralCrossRef

57.

Katsu Y, Oka K, Baker ME (2018) Evolution of human, chicken, alligator, frog, and zebrafish mineralocorticoid receptors: allosteric influence on steroid specificity. Sci Signal 11:eaao1520PubMedCrossRef

58.

Faulkner JL, Kennard S, Huby A-C, Antonova G, Lu Q, Jaffe IZ, Patel VS, Fulton DJR, Belin de Chantemèle EJ (2019) Progesterone predisposes females to obesity-associated leptin-mediated endothelial dysfunction via upregulating endothelial MR (mineralocorticoid receptor) expression. Hypertension 74:678–686PubMedCrossRef

59.

Hirasawa G, Takeyama J, Sasano H, Fukushima K, Suzuki T, Muramatu Y, Darnel AD, Kaneko C, Hiwatashi N, Toyota T, Nagura H, Krozowski ZS (2000) 11Beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human placenta. J Clin Endocrinol Metab 85:1306–1309PubMed

60.

Yakirevich E, Morris DJ, Tavares R, Meitner PA, Lechpammer M, Noble L, de Rodriguez AF, Gomez-Sanchez CE, Wang LJ, Sabo E, DeLellis RA, Resnick MB (2008) Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study. Am J Surg Pathol 32:874–883PubMedCrossRef

Titel: The role of mineralocorticoids and glucocorticoids under the impact of 11β-hydroxysteroid dehydrogenase in human breast lesions
verfasst von: Mingzhen Cai
Keely McNamara
Yuto Yamazaki
Narumi Harada
Minoru Miyashita
Hiroshi Tada
Takanori Ishida
Hironobu Sasano
Publikationsdatum: 01.02.2022
Verlag: Springer Nature Singapore
Erschienen in: Medical Molecular Morphology / Ausgabe 2/2022
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-022-00312-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The role of mineralocorticoids and glucocorticoids under the impact of 11β-hydroxysteroid dehydrogenase in human breast lesions

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Analysis of purple urine bag syndrome by low vacuum scanning electron microscopy

Microvascular system of hip joint constituents with special reference to ultrastructural findings and early arteriosclerosis

Promising therapeutic targets of endometriosis obtained from microRNA studies

Association between mitochondrial and nuclear DNA damages and cellular senescence in the patients with biliary atresia undergoing Kasai portoenterostomy and liver transplantation

Fascin expression persists with fibronectin in embryonic rat hepatoblasts

Protection of rat artery grafts from tissue damage by voltage-applied supercooling

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie